Literature DB >> 26974384

Sulfatase inhibitors for recidivist breast cancer treatment: A chemical review.

Ramanpreet Shah1, Jatinder Singh1, Dhandeep Singh2, Amteshwar Singh Jaggi1, Nirmal Singh1.   

Abstract

Steroid sulfatase (STS) plays a momentous role in the conversion of sulfated steroids, which are biologically inactive, into biologically active un-sulfated steroid hormones, which support the development and growth of a number of hormone-dependent cancers, including breast cancer. Therefore, inhibitors of STS are supposed to be potential drugs for the treatment of breast and other steroid-dependent cancers. The present review concentrates on broad chemical classification of steroid sulfatase inhibitors. The inhibitors reviewed are classified into four main categories: Steroid sulfamate based inhibitors; Steroid non-sulfamate based inhibitors; Non-steroidal sulfamate based inhibitors; Non-steroidal non-sulfamate based inhibitors. A succinct overview of current treatment of cancer, estradiol precursors, STS enzyme and its role in breast cancer is herein described.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast cancer; Non-steroidal non-sulfamate based inhibitors; Non-steroidal sulfamate based inhibitors; Steroid non-sulfamate based inhibitors; Steroid sulfamate based inhibitors; Sulfatase inhibitor's chemistry

Mesh:

Substances:

Year:  2016        PMID: 26974384     DOI: 10.1016/j.ejmech.2016.02.054

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  [Effect of gap junction modulation on antitumor effects of adriamycin in estrogen receptor-positive breast cancer cells].

Authors:  Guojun Jiang; Yaming Liu; Wanchen Zhao; Daoxin Wang; Shuying Dong; Xuhui Tong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

2.  Steroidal ferrocenes as potential enzyme inhibitors of the estrogen biosynthesis.

Authors:  Bianka Edina Herman; János Gardi; János Julesz; Csaba Tömböly; Eszter Szánti-Pintér; Klaudia Fehér; Rita Skoda-Földes; Mihály Szécsi
Journal:  Biol Futur       Date:  2020-06-25

3.  Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents.

Authors:  Leilei Huang; Jinwen Huang; Hui Nie; Yingzi Li; Lixing Song; Fanhong Wu
Journal:  RSC Med Chem       Date:  2021-06-23

Review 4.  Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade.

Authors:  Mateusz Daśko; Sebastian Demkowicz; Karol Biernacki; Olga Ciupak; Witold Kozak; Maciej Masłyk; Janusz Rachon
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  New potent steroid sulphatase inhibitors based on 6-(1-phenyl-1H-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives.

Authors:  Olga Ciupak; Mateusz Daśko; Karol Biernacki; Janusz Rachon; Maciej Masłyk; Konrad Kubiński; Aleksandra Martyna; Sebastian Demkowicz
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

6.  Development of Sulfamoylated 4-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenol Derivatives as Potent Steroid Sulfatase Inhibitors for Efficient Treatment of Breast Cancer.

Authors:  Karol Biernacki; Olga Ciupak; Mateusz Daśko; Janusz Rachon; Witold Kozak; Janusz Rak; Konrad Kubiński; Maciej Masłyk; Aleksandra Martyna; Magdalena Śliwka-Kaszyńska; Joanna Wietrzyk; Marta Świtalska; Alessio Nocentini; Claudiu T Supuran; Sebastian Demkowicz
Journal:  J Med Chem       Date:  2022-03-02       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.